Skip to content

Feed Screener Search Methodology

SEC · FI · BAFIN · AFM · AMF

Pricing Sign in

InsiderLens

Statistics predict. AI explains.

Insider transactions from public regulatory disclosures, aggregated and enriched with deterministic statistical signals. Not investment advice.

Sources

SEC EDGAR · US
FINANSINSPEKTIONEN · SE
BAFIN · DE
AFM · NL
AMF · FR

Product

Methodology
Privacy notice
Object to processing

Feed Screener Search Methodology

Pricing Sign in

Hoyos Rocio Martin — Atrium Therapeutics, Inc. insider: 2 transactions · InsiderLens

Home / Insiders / Hoyos Rocio Martin

Hoyos Rocio Martin

Chief Strategy Officer at Atrium Therapeutics, Inc. · on record since Apr 22, 2026

Insider trading activity of Hoyos Rocio Martin

Transactions on record: 2; since Apr 22, 2026

Open-market buys: 0

Open-market sells: 0

Companies traded: 1; last filing Apr 22, 2026

Figures computed from official regulatory filings — methodology.

Companies where Hoyos Rocio Martin has traded

Atrium Therapeutics, Inc.2 tx · Apr 22, 2026

Track record of Hoyos Rocio Martin

Insufficient history for a statistical track record (fewer than 5 open-market buys).

Transaction history of Hoyos Rocio Martin

Co-insiders of Hoyos Rocio Martin

Alexandria Venture Investments, LLCAtrium Therapeutics, Inc.
Baroldi JosephAtrium Therapeutics, Inc.
BOESS CARSTENAtrium Therapeutics, Inc.
BORON GREGORY FAtrium Therapeutics, Inc.
Boyce SarahAtrium Therapeutics, Inc.
Brady Todd CAtrium Therapeutics, Inc.
Calderaro Charles IIIAtrium Therapeutics, Inc.

This page republishes public regulatory disclosures. Concerned by this data? Exercise your right to object →

Chen BihuaAtrium Therapeutics, Inc.

COMER WILLIAM M JRAtrium Therapeutics, Inc.

Cormorant Asset Management, LPAtrium Therapeutics, Inc.

Cormorant Global Healthcare Master Fund, LPAtrium Therapeutics, Inc.

Cormorant Private Healthcare Fund II, LPAtrium Therapeutics, Inc.

COSTA SANTO JAtrium Therapeutics, Inc.

DIMITRIADIS ANDRE CAtrium Therapeutics, Inc.

Edwards MartinAtrium Therapeutics, Inc.

Flanagan W. MichaelAtrium Therapeutics, Inc.

Gallagher Kathleen P.Atrium Therapeutics, Inc.

Henig NoreenAtrium Therapeutics, Inc.

Hughes Steven GeorgeAtrium Therapeutics, Inc.

ICN PHARMACEUTICALS INCAtrium Therapeutics, Inc.

Kaye Edward M. MDAtrium Therapeutics, Inc.

Kenney StephanieAtrium Therapeutics, Inc.

Kim Jae B.Atrium Therapeutics, Inc.

Kim Jean JinsunAtrium Therapeutics, Inc.

LAMON KIM DAVIDAtrium Therapeutics, Inc.

LEVIN ARTHUR AAtrium Therapeutics, Inc.

LILLY ELI & COAtrium Therapeutics, Inc.

MacLean Michael FAtrium Therapeutics, Inc.

Martin Michael B.Atrium Therapeutics, Inc.

McCarthy TeresaAtrium Therapeutics, Inc.

MEL DEUTSCHAtrium Therapeutics, Inc.

Moriarty John BAtrium Therapeutics, Inc.

Mosbrooker EricAtrium Therapeutics, Inc.

PARACKA DANIELAtrium Therapeutics, Inc.

PIECZYNSKI JAMESAtrium Therapeutics, Inc.

RTW INVESTMENTS, LPAtrium Therapeutics, Inc.

Skerjanec SimonaAtrium Therapeutics, Inc.

SMITH ROBERTSAtrium Therapeutics, Inc.

Thompson TamarAtrium Therapeutics, Inc.

WILSON TROY EDWARDAtrium Therapeutics, Inc.

Winslow Brendan R.Atrium Therapeutics, Inc.

WONG RODERICKAtrium Therapeutics, Inc.

Younis HusamAtrium Therapeutics, Inc.

Company	Filed	Type	Qty	Price	Value · USD	Src
Atrium Therapeutics, Inc.	Apr 22, 2026	Award	30,000	0.00 USD	$0	SEC
Atrium Therapeutics, Inc.	Apr 22, 2026	AwardD	60,000	0.00 USD	$0	SEC